FDA Biosimilar Guidance Should Ease Biologics Development
The U.S. Food and Drug Administration issued new draft guidance on Oct. 29, proposing what it said were "major updates to simplify biosimilarity studies and reduce unnecessary clinical testing."...To view the full article, register now.
Already a subscriber? Click here to view full article